Sphingosine 1-Phosphate Receptor Modulator

Aka: Sphingosine 1-Phosphate Receptor Modulator, S1P Receptor Modulator, Fingolimod, Fingolimod Hydrochloride, Gilenya, Siponimod, Mayzent, Ozanimod, Zeposia, Ponesimod, Ponvory

advertisement

II. Background

  1. Expensive in 2022 (~$10,000/month)

III. Indications

  1. Multiple Sclerosis (relapsing)
    1. Fingolimod (Gilenya)
    2. Siponimod (Mayzent)
    3. Ozanimod (Zeposia)
    4. Ponesimod (Ponvory)
  2. Ulcerative Colitis (active, moderate to severe)
    1. Ozanimod (Zeposia)

IV. Contraindications

  1. Cardiovascular event in last 6 months (e.g. MI, CVA)
  2. Unstable Angina
  3. Atrioventricular Block
  4. Decompensated Congestive Heart Failure (stage 3-4)
  5. Antiarrhythmic use (Class Ia or class III)
  6. QTc Prolongation >500 msec

V. Mechanism

  1. Acts as an Immunosuppressant, decreasing Lymphocyte migration to the Central Nervous System
  2. Sphingosine-1-phosphate receptor blocker (S1P Receptor)
    1. Blockade results in fewer Lymphocytes exiting Lymph Nodes
    2. Decreases autoimmune attack of Myelin Sheath

VI. Medications

  1. Fingolimod (Gilenya)
    1. Adult: 0.5 mg orally daily
    2. Child (age >=10 years)
      1. Weight >40 kg: Use adult dose
      2. Weight <40 kg: 0.25 mg orally daily
  2. Siponimod (Mayzent)
    1. Released in 2020 and similar to Fingolimod
    2. Dosing is adjusted for specific CYP2C9 Genotypes (contraindicated in some Genotypes, test before administration)
  3. Ozanimod (Zeposia)
    1. Released in 2020 and similar to Fingolimod
    2. Dose 0.92 mg orally once daily (see references for dosing adjustments)
  4. Ponesimod (Ponvory)
    1. Released in 2021 and similar to Fingolimod
    2. Dose 20 mg orally once daily (see references for dosing adjustments)

VII. Adverse Effects

  1. Cardiovascular
    1. Hypertension
    2. QTc Prolongation
    3. Bradycardia
      1. May present with Dizziness or Fatigue
      2. Observe for 6 hours after first dose (or after restarting Fingolimod with last dose >14 days)
      3. Avoid in those with known Arrhythmia or other heart disorder
      4. Avoid concurrent use with Digoxin, Diltiazem or Beta Blocker
  2. Hepatotoxicity
    1. Elevated liver transaminases
  3. Uncommon but Serious Adverse Effects
    1. Melanoma
    2. Macular edema
    3. Serious infections
    4. HSV Encephalitis
    5. Progressive Multifocal Leukoencephalopathy (PML)
      1. Onset within 12 to 24 months of Fingolimod
      2. Consider JC Virus Antibody testing
      3. Obtain MRI Brain for new neurologic changes

VIII. Safety

  1. Unknown safety in pregnancy
  2. Unknown safety in Lactation
  3. Monitoring
    1. Complete Blood Count (baseline and periodically)
    2. Ophthalmology for dilated Eye Exam (baseline and after 3-4 months)
    3. Liver Function Tests (baseline)

IX. Drug Interactions

  1. Live Vaccines
    1. Avoid while using Fingolimod and for at least 2 months after
    2. Update Vaccinations (including VZV Vaccine) at least 2 months before treatment
  2. CYP2C9 Inhibitors or Inducers
    1. Siponimod (Mayzent) requires testing for CYP2C9 Genotype before use

X. Resources

  1. Fingolimod (DailyMed)
    1. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cc9e1c8c-0e2b-44e2-878b-27057f786be9
  2. Siponimod (DailyMed)
    1. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44492772-5aed-4627-bd85-e8e89f308bb3
  3. Ozanimod (DailyMed)
    1. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=93ce2fab-edfb-4804-8074-963071de51e4
  4. Ponesimod (DailyMed)
    1. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5be69660-738c-4db7-b0d4-517aa873dc41

Images: Related links to external sites (from Bing)

These images are a random sampling from a Bing search on the term "Sphingosine 1-Phosphate Receptor Modulator." Click on the image (or right click) to open the source website in a new browser window. Search Bing for all related images

Related Studies

Cost: Medications

fingolimod (on 9/20/2023 at Medicaid.Gov Survey of pharmacy drug pricing)
FINGOLIMOD 0.5 MG CAPSULE Generic $9.74 each
gilenya (on 7/27/2022 at Medicaid.Gov Survey of pharmacy drug pricing)
GILENYA 0.5 MG CAPSULE $315.81 each
FPNotebook does not benefit financially from showing this medication data or their pharmacy links. This information is provided only to help medical providers and their patients see relative costs. Insurance plans negotiate lower medication prices with suppliers. Prices shown here are out of pocket, non-negotiated rates. See Needy Meds for financial assistance information. GoodRx is another tool for finding lower drug prices.

Related Topics in Pharmacology

advertisement